Core Insights - Vertex Pharmaceuticals reported third-quarter results that exceeded Wall Street estimates, primarily due to strong demand for its cystic fibrosis treatments and early contributions from newer medications [1] Financial Performance - The company demonstrated robust financial performance in the third quarter, driven by increased sales of cystic fibrosis treatments [1] - Early contributions from newer products also played a significant role in surpassing market expectations [1]